{"id":36356,"date":"2025-05-12T12:00:00","date_gmt":"2025-05-12T12:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4685015_CN85015_0"},"modified":"2025-05-12T12:00:00","modified_gmt":"2025-05-12T12:00:00","slug":"accuredit-therapeutics-to-present-at-the-2025-annual-meeting-of-the-american-society-of-gene-cell-therapy","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=36356","title":{"rendered":"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy"},"content":{"rendered":"\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SUZHOU, China<\/span><\/span>, May 12, 2025<\/span><\/span> \/PRNewswire\/ — AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th<\/sup> Annual Meeting being held from May 13-17, 2025<\/span>, in New Orleans, LA<\/span>.<\/p>\n

ART001 is the only LNP-based in vivo<\/i> gene editing product that has cleared INDs in both the US and China<\/span>. It is currently in phase I\/IIa studies in China<\/span> and phase I study in the US.<\/p>\n

The two poster presentations focus on ART002 and ARTbase-A1\u2122, respectively. ART002 is AccurEdit Therapeutics’ second pipeline product that has achieved nearly 90% reduction in PCSK9 and 56% reduction in LDL-C on average in HeFH patients with critically high LDL-C baselines (>6 mM). ARTbase-A1\u2122 is AccurEdit Therapeutics’ solely-owned base editor platform that has recently been granted patents in China<\/span> and the US. <\/p>\n

“We thank the organizing committee of ASGCT for the opportunity to present the latest data on our pipeline products with best-in-class potentials and novel gene-editing tools with industry-leading performances.” said Yongzhong Wang<\/span>, Ph.D., CEO of AccurEdit Therapeutics. “We look forward to meeting our peers and potential collaborators to discuss the exciting perspective of delivering more efficient, safe and affordable in vivo<\/i> gene therapeutics for our patients globally.”<\/p>\n

Oral Presentation Details<\/b><\/p>\n

Abstract Title:<\/b> ART001: Development and Interim Clinical Outcomes of a CRISPR-Based In Vivo Gene-Editing Therapy for Hereditary ATTR
Oral Presentation Date\/Time: <\/b>Friday, May 16, 2025<\/span> at 5:15 PM – 5:30 PM CT<\/span>
Room: <\/b>Room 393-396
Final Abstract Number: AMA434<\/b><\/p>\n

Poster Presentation Details<\/b><\/p>\n

Abstract Title:<\/b> Efficacy and Safety of ART002, a Single-dose Gene Editing Therapy, in Patients with Severe Heterozygous Familial Hypercholesterolemia
Poster Session Date\/Time:<\/b> Tuesday, May 13, 2025<\/span> at 6:00 PM – 7:30 PM CT<\/span>
Room: <\/b>Poster Hall Hall I2
Final Abstract Number: AMA562<\/b><\/p>\n

Abstract Title:<\/b> Engineering TadA-Derived Base Editors with Enhanced Potency and Safety for non-viral In Vivo Gene Editing<\/i>
Poster Session Date\/Time: <\/b>Thursday, May 15, 2025<\/span> at 5:30 PM – 7:00 PM CT<\/span>
Room: <\/b>Poster Hall Hall I2
Final Abstract Number: AMA559<\/b><\/p>\n

About AccurEdit Therapeutics: <\/b><\/p>\n

AccurEdit Therapeutics, founded in 2021, focuses on developing in vivo gene editing technologies and therapeutics based on LNP (lipid nanoparticle) and other non-viral delivery systems. The company is dedicated to providing innovative one-time treatment solutions with cost advantages for patients worldwide.<\/p>\n

The company boasts a professional team with full-lifecycle experience in successful biologics development and has established the world’s first clinically validated, industry-grade, end-to-end in vivo gene editing platform. It has systematically built intellectual property portfolios for related technologies and products, including ARTbase-A1\u2122, a novel base editor that has been granted a U.S. patent.<\/p>\n

AccurEdit Therapeutics has developed a pipeline targeting genetic rare diseases and refractory common disorders. In August 2023<\/span>, its ATTR-targeted therapy ART001 became China’s<\/span> first LNP-delivered in vivo gene editing drug to enter human clinical trials. By August 2024<\/span>, ART001 further achieved another milestone as the first and only product of its kind in China<\/span> to receive U.S. FDA clinical trial approval. In February 2025<\/span>, ART002, targeting HeFH (PCSK9), emerged as the world’s first in vivo gene editing therapy to demonstrate therapeutic saturation in humans, effectively reducing LDL-C in patients with extremely high baseline levels. Both ART001 and ART002 have shown safety and efficacy data with the potential to become global best-in-class therapies.<\/p>\n

BD Contact: Accuredit@accuredit.com<\/a>
PR Contact: tingting.zhang@accuredit.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

SUZHOU, China, May 12, 2025 \/PRNewswire\/ — AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting being held from May 13-17, 2025, in New Orleans, LA. ART001 is the only LNP-based in vivo […]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-36356","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"\nAccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=36356\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy - My Blog\" \/>\n<meta property=\"og:description\" content=\"SUZHOU, China, May 12, 2025 \/PRNewswire\/ — AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting being held from May 13-17, 2025, in New Orleans, LA. ART001 is the only LNP-based in vivo […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=36356\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-12T12:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1725691\/Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy\",\"datePublished\":\"2025-05-12T12:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356\"},\"wordCount\":573,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1725691\\\/Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356\",\"name\":\"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1725691\\\/Logo.jpg?p=medium600\",\"datePublished\":\"2025-05-12T12:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1725691\\\/Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1725691\\\/Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=36356#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=36356","og_locale":"en_US","og_type":"article","og_title":"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy - My Blog","og_description":"SUZHOU, China, May 12, 2025 \/PRNewswire\/ — AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting being held from May 13-17, 2025, in New Orleans, LA. ART001 is the only LNP-based in vivo […]","og_url":"https:\/\/transmediavictoria.net.au\/?p=36356","og_site_name":"My Blog","article_published_time":"2025-05-12T12:00:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1725691\/Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=36356#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=36356"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy","datePublished":"2025-05-12T12:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=36356"},"wordCount":573,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=36356#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1725691\/Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=36356","url":"https:\/\/transmediavictoria.net.au\/?p=36356","name":"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=36356#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=36356#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1725691\/Logo.jpg?p=medium600","datePublished":"2025-05-12T12:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=36356#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=36356"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=36356#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1725691\/Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1725691\/Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=36356#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/36356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36356"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/36356\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}